<DOC>
	<DOCNO>NCT00633217</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety FSC HFA MDI subject COPD . The dose FSC HFA MDI evaluate corresponds dose FSC DISKUS ( 250/50mcg twice-daily ) indicate treatment COPD associate chronic bronchitis US . This study last approximately 15 week , subject visit clinic 5 time . Subjects give breathe test record peak expiratory flow measurement daily diary card . All study relate medicine medical examination provide cost . The FSC HFA MDI use study approve FDA use asthma FSC 250/50mcg DISKUS approve use asthma COPD .</brief_summary>
	<brief_title>Advair HFA For Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Subjects eligible enrollment study must meet following criterion : Signed date write informed consent obtain subject and/or subject 's legally acceptable representative prior study participation . Males females ≥ 40 year age . A female eligible participate study : 1. nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal [ i.e. , &gt; 1 year without menses absence hormone replacement therapy ] ) ; , 2. childbearing potential , negative pregnancy test ( urine ) screen , one follow applies : Abstinence intercourse , , Male partner sterile prior female subject 's entry study , , Use implant levonorgestrel ; , Injectable progesterone ; , Oral contraceptive ( combine progesterone ) , contraceptive patch , vaginal ring ; , Any intrauterine device ( IUD ) publish data show high expected failure rate le 1 % per year ( e.g. , Paragard ) , , Double barrier technique simultaneously use two follow : spermicide , male condom , diaphragm , female condom An establish clinical history COPD ( include chronic bronchitis and/or emphysema ) accordance follow definition American Thoracic Society : COPD preventable treatable disease state characterise airflow limitation fully reversible . The airflow limitation usually progressive associate abnormal inflammatory response lungs noxious particle gas , primarily cause cigarette smoking . Although COPD affect lung , also produce significant systemic consequence [ Celli , 2004 ] . A postalbuterol FEV1/FVC ratio ≤ 0.70 A postalbuterol FEV1 ≥ 0.70L ≤ 70 % predict normal OR postalbuterol FEV1 ≤ 0.70L ≥40 % predict normal still ≤70 % predict normal base NHANES III reference value [ Hankinson , 1999 ] . Current previous smoker cigarette smoke history ≥ 10 packyears . [ number pack year = ( number cigarette per day / 20 ) x number year smoke ( e.g. , 10 packyears equal 20 cigarette per day 10 year , 10 cigarette per day 20 year ] . Formersmokers define subject discontinue smoke ≥ 6 month prior Visit 1 . Subjects decide stop smoking Visit 1 eligible participation study . Subjects meet follow criterion must enrol study : A current diagnosis asthma . Any clinically significant uncontrolled disease , include limited following : neurological , psychiatric , renal , immunological , endocrine/metabolic ( include uncontrolled diabetes , hypokalemia thyroid disease ) , cardiovascular , neuromuscular , hepatic , gastric , hematological abnormality , peripheral vascular disease . Significant define disease , opinion investigator , would put safety subject risk study participation would affect efficacy analysis disease/condition exacerbate study . A respiratory diagnosis COPD ( e.g. , lung cancer , bronchiectasis , sarcoidosis , tuberculosis , lung fibrosis ) , include subject diagnosis alpha1antitrypsin deficiency . Allergic rhinitis exclusionary . An abnormal clinically significant chest xray compute tomography ( CT ) scan believe due presence COPD . A chest xray must take subject one within 6 month Visit 1 . An abnormal clinically significant 12lead electrocardiogram ( ECG ) . For purpose study , abnormal ECG define 12lead tracing interpret ( limit ) follow : Myocardial ischemia Clinically significant conduction abnormality ( e.g. , leave bundle branch block , WolffParkinsonWhite syndrome ) Clinically significant arrhythmia ( e.g. , atrial fibrillation , ventricular tachycardia ) The study investigator determine clinical significance ECG abnormality determine subject preclude enter study . Previously diagnose cancer unless complete clinical remission ( evidence tumor burden ) Visit 1 . Localized carcinoma skin resect cure consider exclusionary . Any immediate delay hypersensitivity betaagonist , sympathomimetic drug , intranasal , inhale , oral corticosteroid include component formulation ( e.g . lactose milk protein ) . Initiation systemic betablocker medication within 30 day Visit 1 . Use product contain protease inhibitor ritonavir ( Norvir , Kaletra ) . Use following medication within define time prior Visit 1 : Medication ( Exclusion Prior Visit 1 ) Shortacting betaagonists ( e.g. , albuterol ) ( 6 hour ) Ipratropium ( 6 hour ) Ipratropium/albuterol combination product ( 6 hour ) Oral betaagonists ( 48 hour ) Salmeterol formoterol ( 48 hour ) Theophylline preparation ( 48 hour ) Tiotropium ( 48 hour ) Longacting betaagonist/inhaled corticosteroid combination product ( e.g. , ADVAIR™ Symbicort ) ( 30 day ) Inhaled corticosteroid ( 30 day ) Oral parenteral corticosteroid ( 30 day ) Any investigational drug ( 30 day ) Lung resection surgery ( e.g. , lung volume reduction surgery , lobectomy ) within 1 year Visit 1 . A COPD exacerbation and/or infection upper low respiratory tract require treatment systemic ( oral parenteral ) corticosteroid and/or antibiotic resolve within 30 day Visit 1 A COPD exacerbation result hospitalization resolve within 3 month Visit 1 . Use nocturnal positive pressure [ e.g. , continuous positive airway pressure bilevel positive airway pressure ] . A body mass index ( BMI ) ≥ 40kg/m² . Subject study investigator , subinvestigator , study coordinator , employee participate investigator immediate family member aforementioned . Any intellectual deficiency include illiteracy , history substance abuse two year prior Visit 1 ( include drug alcohol ) , condition , limit validity inform consent participate study . Supplemental oxygen , follow exception : Use high altitude ( &gt; 5000 foot ) provide subject require flow rate &gt; 2 L/minute Use exertion provide subject require &gt; 2 hour per day oxygen require flow rate &gt; 2L/minute Use nocturnal therapy provide subject require flow rate &gt; 2L/minute</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>DISKUS</keyword>
	<keyword>Salmeterol</keyword>
	<keyword>Fluticasone Propionate</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
	<keyword>Hydroflouroalkane</keyword>
	<keyword>COPD</keyword>
	<keyword>HFA MDI</keyword>
</DOC>